

## DEPARTMENT OF DEFENSE FREEDOM OF INFORMATION DIVISION 1155 DEFENSE PENTAGON WASHINGTON, DC 20301-1155

Ref: 19-F-1910

SEP 2 7 2019

Dr. Remington Nevin MuckRock News DEPT MR 70910 411A Highland Ave Somerville, MA 02144-2516

Dear Dr. Nevin:

This is an interim response to your March 24, 2019 Freedom of Information Act (FOIA) request, a copy of which is enclosed for your convenience. We received your request on September 23, 2019, and assigned it case number 19-F-1910. We ask that you use this number when referring to your request

Although we have already begun processing your request, we will not be able to respond within the FOIA's 20-day statutory time period as there are unusual circumstances which impact our ability to quickly process your request. The FOIA defines unusual circumstances as (a) the need to search for and collect records from a facility geographically separated from this office; (b) the potential volume of records responsive to your request; and (c) the need for consultation with one or more other agencies or DoD components having a substantial interest in either the determination or the subject matter of the records. At least one, if not more of these scenarios applies or would likely apply to your request. While this office handles FOIA requests for the Office of the Secretary of Defense (OSD), the Joint Staff (JS) and other component offices, we do not actually hold their records and our office is not geographically located with these organizations. As we do not hold the records, until the required records searches are complete, we are unable to estimate the potential volume of records or the number of consultations that will be required to make a release determination.

Your request has been placed in our complex processing queue and is being worked based on the order in which the request was received. Our current administrative workload is approximately 2,987 open requests.

In some instances, we have found that requesters who narrow the scope of their requests experience a reduction in the time needed to process their requests.

The OSD/JS FOIA Public Liaison, Darrell Williams, is available at 571-3 72-0462 or by email at OSD.FOIALiaison@mail.mil to answer any concerns about the foregoing.

Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows:

Office of Government Information Services National Archives and Records Administration 8601 Adelphi Road-OGIS College Park, MD 20740

E-mail: ogis@nara.gov Telephone: 202-741-5770

Fax: 202-741-5769

Toll-free: 1-877-684-6448

We regret the delay in responding to your request and appreciate your patience. If you have any questions or concerns about the foregoing or about the processing of your request, please do not hesitate to contact Ms. Joan Haynesworth, at <u>joan.l.haynesworth.ctr@mail.mil</u> or 571-372-0428.

Sincerely,

Stephanie L. Carr

Chief

Enclosure: As stated

14-4-1411)

All active links contained in this email were disabled. Please verify the identity of the sender, and confirm the authenticity of all links contained within the message prior to copying and pasting the address to a Web browser.

Defense Bealth Agency FOIA Office Suite 5101 7700 Arlington Boulevard Falls Church (VVVD)42/5101

March 24, 2019

DHA Freedom of Information Service Center 7700 Arlington Boulevard, Suite 3101 Falls Church, Virginia 22042-5101 Phone: 1-703-275-6363 Fax: 1-703-275-6386 DHA FOIA@mail mil

Re: FOIA Request

To Whom It May Concern:

This is a request under the Freedom of Information Act. I hereby request the following records:

Copies of all correspondence, memorandum, meeting agendas, minities, and any other documents, related to planned, proposed, or enacted Assistant Secretary of Defense (Health Affairs) policy for the use of safenoquine, to include any records related to updating the "DoD Guidance for Malaris Prophylaxas" policy, discussed in the Tafenoquine Transition Planning Meeting (enclosed).

The requested documents will be made available to the general public, and this request is not being made for commercial purposes.

In the event that there are fees, I would be grateful if you would inform me of the total charges in advance of fulfilling my request. I would prefer the request filled electronically, by e-mail attachment if available or CD-ROM if not.

Thank you in advance for your anticipated cooperation in this matter. I look forward to receiving your response to this request within 20 business days, as the statute requires

Sincerely.

Dr. Remington Nevin

Filed via MuckBock.com

E-mail (Preferred): 79910-56636139@requests muckrock.com

Upload documents directly: Caution-littles/new-mackrock comvaccounts/agency-login defense-health-agency-4190-documents-related-to-updating-the-sadia-dod-guidance-for-malans-prophylaxus-policy-to-include-use-of-tafenoquine-70910 "nuid-login-de9fab38-781c-481s-bRob-bd38e101331 &cmail-oda-ance printings-for-malans-prophylaxus-policy-to-include-use-of-tafenoquine-70910 "nuid-login-de9fab38-781c-481s-bRob-bd38e1013" &cmail-oda-an

For mailed responses, please address (see note). MuckRock News DEPT MR 70910 411A Highland Ave Somerville, MA 02144-2516

PLEASE NOTE: This request is not filled by a MuckRock staff member, but is being sent through MuckRock by the above in order to better track, share, and manage public records requests. Also note that improperly addressed (i.e., with the requester's name nather than "MuckRock by the above in order to better track, share, and manage public records requests. Also note that improperly addressed (i.e., with the requester's name nather than "MuckRock by the above in order to better track, share, and manage public records requests. Also note that improperly addressed (i.e., with the requester's name nather than "MuckRock by the above in order to better track, share, and manage public records requests."

<Q aution-lttp://mail.requests.muckreck.com.org/w1zUEOm/aQQXIII1yMIJAAMMCchde:ATThQEgylUBsDXVA\_3SQmiVx0Fx0RdSMgbal.holbyGQDEyOsumwifeR9IIOTRDhnZTGBWUJIKTDG8QCGyWyszWegV9MYOMsDagl.GullsTuyXcYyJJJcR7l.his wfgCdnr4ammwxX2>

14-4-140 Page:

Ai	rakoda™ (Tatenoquine) Transition Planning	Meeting Agenda
	(b)(5) 0900-1000 (East Co	
	Location: USAMMDA Bldg 1430, (6)(5)	
	(b)(5)	
1. Introduction	ns, Purpose of Working Group	(b)(6) (b)(6)
2. Review of I	Issues	(b)(6)
3. Commercia	alization Plan	(b)(6)
4. Modification	n of DOD Guidance for Malaria Prophylaxis	(b)(6)
	f <i>Arakoda</i> ™ onto DOD Peacetime Procurement and Contingency Contracts	(b)(6)
6. Inclusion of	f <i>Arakoda</i> ™ onto DOD Formularies	(b)(6) .
7. Final Discus	ession	

)		
EETING V	WITH 60P TO DISCUSS TAFENOQUINE CO	MMERCIALIZATION
RTICIPAL	NTS: (D)(6)	
5)		
scussio	N:	
	-	; 6 months for FDA review (completed NLT 8 Augu
• (b)(4	18)	
L	neline:	
• iin	neiine:	
	FDA approval	8 August 2018
	Tablet validation	(b)(4)
	Packaging validation	(b)(4)
	Serialization validation	(b)(4)
	Validation lots shipped to distributor	(b)(4)
	Commercial launch	(b)(4)
• Bri	hite paper for consultant community? ief at MHSRS (60P brief) ho at DoD-HA can guide us as to how to a	pproach them to get the word out?
• (b)(5	5)	
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3
• Ca	n industry reps approach individual MTFs	of the state of th
. Th	ree (3) validation lots will have (6)(4)	
	Unit of purchase is (b)(4)	
0		hylaxis for one service member for 1 month.
Ü	One Unit of purchase will provide prop	
Ω		
0	Unit of purchase cost = (b)(4)	
0	Unit of purchase cost = (b)(4) tablet)	(estimate, based on estimated cost of (b)(4)
	Unit of purchase cost = (b)(4) tablet) Cost of the 3 validation lots is estimated	(estimate, based on estimated cost of (b)(4)
0	Unit of purchase cost = (b)(4) tablet) Cost of the 3 validation lots is estimated	(estimate, based on estimated cost of $(b)^{(4)}$ of at $(b)^{(4)}$ amount to support placebo-controlled studies?
0	Unit of purchase cost = (b)(4) tablet)  Cost of the 3 validation lots is estimated (b)(6) could we commit to buying this perhaps post-market night vision studie	d at (b)(4) amount to support placebo-controlled studies? es? Tolerability studies?
0	Unit of purchase cost = (b)(4) tablet)  Cost of the 3 validation lots is estimated (b)(6)  could we commit to buying this perhaps post-market night vision studie gistics: (b)(4) is the Third Party Logistician (p	d at (b)(4) amount to support placebo-controlled studies? es? Tolerability studies?
• Lo	Unit of purchase cost = (b)(4) tablet)  Cost of the 3 validation lots is estimated (b)(6) could we commit to buying this perhaps post-market night vision studie	d at (b)(4) amount to support placebo-controlled studies? es? Tolerability studies?
• <b>Lo</b>	Unit of purchase cost = (b)(4)  tablet)  Cost of the 3 validation lots is estimated (b)(6)  Could we commit to buying this perhaps post-market night vision studie (gistics: (b)(4)) is the Third Party Logistician (perhaps can also do serialization  From (b)(4) → Wholesalers (c)(4)	(estimate, based on estimated cost of (b)(4) point at (b)(4) amount to support placebo-controlled studies?  es? Tolerability studies?

• Si	ummary of Potential Actions for USAMMDA:		
	o Can the Army commit to buying a certain amount of TQ to support post-marketing		
	studies?		
	o Can industry reps approach individual MTFs?		
	O (b)(4)		
	Who at DoD-HA can we contact reference TQ?		
	<ul> <li>When are future JPMPG quarterly meetings?</li> </ul>		
	Can we persuade DoD-HA to recommend TQ for malaria treatment?		
	<ul> <li>Can we get TQ into the appropriate unit assemblages? Need to engage the USAMMA pharmacist.</li> </ul>		
	(on/about)		
IBJECT:	POTENTIAL COURSES OF ACTION TO FUND PROCUREMENT OF TAFENOQUINE		
cording	to <sup>(b)(6)</sup> , some courses of action:		
• (b	)(5)		
_	5)		
• (b)(			
• (b)(	5)		